Nomura Holdings Inc. acquired a new stake in shares of Savara Inc (NASDAQ:SVRA) during the second quarter, Holdings Channel.com reports. The fund acquired 182,500 shares of the company’s stock, valued at approximately $496,000.
Other institutional investors and hedge funds also recently made changes to their positions in the company. Sullivan Bruyette Speros & Blaney LLC bought a new stake in Savara in the second quarter worth approximately $38,000. DekaBank Deutsche Girozentrale grew its position in Savara by 67.5% in the second quarter. DekaBank Deutsche Girozentrale now owns 20,600 shares of the company’s stock worth $50,000 after acquiring an additional 8,300 shares in the last quarter. Parametric Portfolio Associates LLC bought a new stake in Savara in the second quarter worth approximately $59,000. United Capital Financial Advisers LLC bought a new stake in Savara in the second quarter worth approximately $61,000. Finally, Metropolitan Life Insurance Co NY bought a new stake in Savara in the first quarter worth approximately $83,000. 41.19% of the stock is currently owned by hedge funds and other institutional investors.
Several research firms have commented on SVRA. ValuEngine raised shares of Savara from a “sell” rating to a “hold” rating in a research report on Thursday, August 1st. HC Wainwright decreased their target price on shares of Savara from $22.00 to $6.00 and set a “buy” rating for the company in a research report on Thursday, June 13th. LADENBURG THALM/SH SH reissued a “hold” rating and issued a $1.00 target price on shares of Savara in a research report on Thursday. BidaskClub downgraded shares of Savara from a “strong-buy” rating to a “buy” rating in a research report on Friday, June 14th. Finally, Evercore ISI set a $17.00 target price on shares of Savara and gave the stock a “buy” rating in a research report on Monday, August 12th. Five analysts have rated the stock with a hold rating and four have given a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus target price of $9.09.
Savara (NASDAQ:SVRA) last released its earnings results on Thursday, August 8th. The company reported ($0.38) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.43) by $0.05. Research analysts anticipate that Savara Inc will post -1.65 earnings per share for the current fiscal year.
Savara Company Profile
Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.
See Also: What does an outperform rating mean?
Want to see what other hedge funds are holding SVRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Savara Inc (NASDAQ:SVRA).
Receive News & Ratings for Savara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Savara and related companies with MarketBeat.com's FREE daily email newsletter.